Surgeons must repeatedly abandon outmoded operative techniques and master new surgical approaches if they are to provide their patients with the most effective treatment available. In psychiatry, we too must revise our approaches in response to the emergence of new knowledge. Possibly, revision of pharmacotherapeutic practice is relatively less challenging in this regard. We are accustomed to the continuing development and release of new drugs for the treatment of depression and we are familiar with shifts from one generation of drugs to the next that sweep through professional practice, heralded by reports of clinical trial findings and accompanied by extensive advertising and marketing efforts by the pharmaceutical industry. Nonetheless, we have learned that such sea changes in pharmacotherapy are often choppy. After riding on a wave of initial fanfare and optimistic proclamations about the potential superiority of new-generation medications, once in widespread use, some will be found to have disappointing results or will be accompanied by unforeseen dangers and, ultimately, will sink. Other new medications will be found to provide true benefits over previous agents. To be able to discern risks, costs, and benefits well, we will need to ensure that high-quality, unbiased research is conducted, interpreted properly, disseminated, and used widely. In Canada, we are lacking adequate mechanisms for timely knowledge exchange that mental health practitioners and consumers can rely on to be credible and sound. One of the goals of the new Mental Health Commission of Canada is to address this gap in knowledge exchange, 6 thus we can be optimistic that appropriate mechanisms may become more available.
Possibly, it is more of a challenge to incorporate and use new knowledge about psychosocial interventions and treatments. An example of this may be identified by tracing the emergence of cognitive behavioural therapy (CBT) and interpersonal therapy (IPT) for depression. Following their introduction in the 1980s, CBT and IPT were demonstrated to be effective and safe interventions for most people with depression. Nonetheless, many Canadian mental health service providers treating people with depression did not incorporate CBT or IPT into their armamentaria, and evidence-based psychosocial treatment for depression remains largely inaccessible. In Dr Andrews' paper, 2 we are provided with some strategies that may result in wider dissemination of evidence-based psychosocial treatments. However, these will require changes in the way services for depression are delivered. Given the substantial disability and suffering that results from depressive disorders, and considering that most clinical guidelines recommend that CBT and IPT be made available as important treatment options, it is surprising that we do not find more health care practitioners in Canada taking up these treatments. There may be various factors contributing to the lacklustre uptake of CBT and IPT for depression in Canadian health care services. Nevertheless, one must consider whether this constitutes, at least in part, an indication of the resistance to change in practice that I have suggested.
It is probably fair to say that we have a great distance to go in delivering the potential benefit that psychosocial treatment could provide to people with depression in Canada. In his paper, Dr Andrews discusses some innovative strategies that may help to widen the reach of psychosocial treatment to individuals with depression.
Perhaps the most difficult challenges we face in reconsidering depression concern our fundamental understanding of the problem itself and its distribution amongst the population. This topic is a focus of Dr Patten's and Dr Andrews' papers. They have summarized some important information that calls for a profound reconceptualization of depressive disorder.
In previous debates about depression, there has been dispute about whether the size of the problem has been exaggerated or underestimated. I have previously described the puffer phenomenon 7 -the spurious inflation of prevalence and incidence rates, named with an allusion to the pufferfish, members of the family Tetraodonitidae, known for their propensity to inflate with air and appear substantially larger than their normal size (Figure 1 ). In describing this phenomenon, I have argued that clinicians, researchers, and consumers have a tendency to inflate the size of a problem, in part to advocate for its importance and the need for services and supports. Evidence for the puffer phenomenon can be found by comparing prevalence rates reported second-hand on websites and in textbooks, policy papers, and journal publications, with rates determined first-hand in epidemiologic studies. Reports published second-hand tend to be high, possibly because they strive to maximize recognition of the significance of any particular condition. In contrast, there is an indication that some estimates of depression prevalence have been too low, particularly when considering rates across the lifetime. Dr Patten and Dr Andrews discuss this topic and describe the importance of considerations about duration of illness, symptom severity, course, and functional ability. They also show that, if we are to take a population-based view of depression, we must shed some of our previously-held notions about the condition. Importantly, this also forces a reconsideration of our approach to depression at a systems level and some key considerations for such system reform are discussed here.
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